We are live on ! Find out more

Eli Lilly

LLY

Market cap $1.04T

1,161.98 USD

-19.91

1.68%

At close Updated Sep 25, 10:54 AM EDT

1 day

-1.68%

5 days

1.53%

1 month

-5.81%

3 months

3.04%

6 months

26.81%

Year to date

7.55%

1 year

62.61%

5 years

413.24%

10 years

1,361.24%

About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Employees: 50,000

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 57.9%

Neutral 30.1%

Negative 12%

NTHM's Index Rebalance Puts Thematic Rotation to Work

The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP-1 weight loss drug manufacturers and midstream energy join the index, while battery technology & storage and software-as-a-service (SaaS) exit.

NTHM's Index Rebalance Puts Thematic Rotation to Work

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market share. Meanwhile, Lilly continues to chip away at the company's position in the market – including in the burgeoning obesity pill space.

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

The Motley Fool

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?

AbbVie is aggressively expanding its newer immunology and oncology drugs to offset the loss of exclusivity for its top legacy treatments. Eli Lilly and is experiencing massive revenue growth fueled by high demand for its cardiometabolic health and weight-loss medications.

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?

TRex Bio Files For IPO As Collaboration With Eli Lilly Deepens

TRex Bio is a clinical-stage biopharma targeting autoimmune and inflammatory diseases, with a lead program in Phase 1b trials for treating atopic dermatitis. TRXB's deepening collaboration with Eli Lilly, including milestone payments and potential IPO participation, signals strong strategic backing and validation. The company is well-capitalized, with a high-quality and diverse investor syndicate, but will require further funding beyond the IPO.

TRex Bio Files For IPO As Collaboration With Eli Lilly Deepens

FDA approves Eli Lilly's once-weekly insulin injection for type 2 diabetes

The once-weekly treatment could reduce the number of injections by more ⁠than 300 per year compared with once-daily basal insulin, Eli Lilly said.

FDA approves Eli Lilly's once-weekly insulin injection for type 2 diabetes

US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes

The US Food and Drug Administration has approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, the drugmaker said on Thursday, offering patients ‌an alternative to daily long-acting insulin injections.

US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes

China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion

Chinese drugmaker InnoCare ‌Pharma said on Thursday it entered ⁠into a research collaboration and license agreement with Eli Lilly ‌that ⁠could be worth up to ⁠about $3.35 billion.

China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion

The Motley Fool

Could Retatrutide Be Worth $10 Billion to Eli Lilly?

Eli Lilly has a deep pipeline in its core therapeutic area. Its next-gen obesity drug, retatrutide, posted excellent results in Phase 3 studies.

Could Retatrutide Be Worth $10 Billion to Eli Lilly?

Viking's Obesity Edge May Be Staying Power, Not Weight Loss

Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their weight loss after switching from weekly shots to every-other-week or monthly dosing.

Viking's Obesity Edge May Be Staying Power, Not Weight Loss

24/7 Wall Street

Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year

Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.

Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year

See News Rankings

Price charts implemented using Lightweight Charts™